Sequential observations of in vitro responses of lymphocytes to phytohemagglutinin in patients receiving gold therapy for rheumatoid arthritis
- PMID: 114640
Sequential observations of in vitro responses of lymphocytes to phytohemagglutinin in patients receiving gold therapy for rheumatoid arthritis
Abstract
Forty-seven patients receiving gold therapy for rheumatoid arthritis were observed sequentially at 6-monthly intervals. When the disease was in remission, and remained so, the in vitro responses of lymphocytes to phylohemagglutinin stimulation tended to be normal. Improvement in the disease were associated with improvement in lymphocyte response and deterioration associated with depression of response. Our observations suggest that these changes are a reflection of disease activity and their relationship to gold therapy is indirect.
Similar articles
-
In vivo and in vitro effects of gold salts on lymphocyte transformation responses and antibody dependent cell-mediated cytotoxicity.J Rheumatol. 1979 Sep-Oct;6(5):527-33. J Rheumatol. 1979. PMID: 118255
-
The immunological consequences of gold therapy: a prospective study in patients with rheumatoid arthritis.Clin Exp Immunol. 1986 Mar;63(3):614-20. Clin Exp Immunol. 1986. PMID: 3086003 Free PMC article.
-
[A case of interstitial pneumonia in polymyositis difficult to distinguish from gold pneumonitis].Nihon Kyobu Shikkan Gakkai Zasshi. 1995 Jul;33(7):745-9. Nihon Kyobu Shikkan Gakkai Zasshi. 1995. PMID: 7564001 Japanese.
-
[Effects of therapy, serology, stage and activity of rheumatoid arthritis on lymphocyte stimulation in whole blood].Z Rheumatol. 1983 May-Jun;42(3):101-3. Z Rheumatol. 1983. PMID: 6880408 German.
-
Disease-modifying agents in rheumatoid arthritis.Ryumachi. 1987 Dec;27(6):409-12. Ryumachi. 1987. PMID: 2455354 Review. No abstract available.
Cited by
-
Changes in mononuclear cell function in patients with rheumatoid arthritis following treatment with auranofin.Clin Rheumatol. 1984 Mar;3 Suppl 1:25-32. doi: 10.1007/BF03342619. Clin Rheumatol. 1984. PMID: 6432410 Clinical Trial.